As shown in phase 3 clinical trial of locally advanced or metastatic non-squamous NSCLC patients without EGFR or ALK genomic aberration, NCT03607539, Sintilimab (anti-PD-1) plus pemetrexed and platinum had a longer median PFS (8.9 versus 5.0 months) and a better ORR (51.9% versus 29.8%) than that in the placebo plus pemetrexed and platinum group (214). Here, ALK is linked to non-small cell lung carcinoma.